Načítá se...
Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma
INTRODUCTION: Breakthroughs in targeted therapy have significantly improved outcomes for many patients with advanced melanoma, including those with BRAFV600 mutant disease. Targeted therapy for BRAFV600-mutant metastatic melanoma includes combinations of BRAF inhibitors and MEK inhibitors, which imp...
Uloženo v:
| Vydáno v: | Expert Opin Orphan Drugs |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6296476/ https://ncbi.nlm.nih.gov/pubmed/30574432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2018.1512402 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|